Seagen Drug Patent Portfolio

Seagen owns 1 orange book drug protected by 8 US patents Given below is the list of Seagen's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11207324 Treatment of HER2 positive cancers 27 Apr, 2038
Active
US11666572 Treatment of HER2 positive cancers 27 Apr, 2038
Active
US12048698 Treatment of HER2 positive cancers 27 Apr, 2038
Active
US11504370 Treatment of brain cancer 25 Mar, 2033
Active
US9457093 Solid dispersions of a ERB2 (HER2) inhibitor 12 Oct, 2032
Active
US8648087 N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases 12 Apr, 2031
Active
US9693989 N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases 09 May, 2027
Active
US7452895 Quinazoline analogs as receptor tyrosine kinase inhibitors 16 Nov, 2024
Active


Given below is the list of recent legal activities going on the following drug patents of Seagen.

Activity Date Patent Number
Patent litigations
Email Notification 29 May, 2024 US9693989
Mail Pre-Exam Notice 29 May, 2024 US9693989
Change in Power of Attorney (May Include Associate POA) 29 May, 2024 US9693989
Patent eCofC Notification 16 Apr, 2024 US11666572
Email Notification 16 Apr, 2024 US11666572
Mail Patent eCofC Notification 16 Apr, 2024 US11666572
Recordation of Patent eCertificate of Correction 16 Apr, 2024 US11666572
Post Issue Communication - Certificate of Correction 29 Mar, 2024 US11666572
Payment of Maintenance Fee, 8th Year, Large Entity 14 Mar, 2024 US9457093
transaction for FDA Determination of Regulatory Review Period 30 Nov, 2023 US9457093
transaction for FDA Determination of Regulatory Review Period 30 Nov, 2023 US9693989
transaction for FDA Determination of Regulatory Review Period 30 Nov, 2023 US8648087
transaction for FDA Determination of Regulatory Review Period 30 Nov, 2023 US7452895
transaction for FDA Determination of Regulatory Review Period 29 Nov, 2023 US9693989
transaction for FDA Determination of Regulatory Review Period 29 Nov, 2023 US7452895


Seagen Drug Patents' Oppositions Filed in EPO

Seagen drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 01, 2021, by Sandoz Ag. This opposition was filed on patent number EP18162971A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP18162971A Sep, 2021 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP18162971A Sep, 2021 Sandoz AG Granted and Under Opposition


Seagen's Family Patents

Seagen drugs have patent protection in a total of 43 countries. It's US patent count contributes only to 18.4% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Seagen Drug List

Given below is the complete list of Seagen's drugs and the patents protecting them.


1. Tukysa

Tukysa is protected by 8 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11207324 Treatment of HER2 positive cancers 27 Apr, 2038
(13 years from now)
Active
US11666572 Treatment of HER2 positive cancers 27 Apr, 2038
(13 years from now)
Active
US12048698 Treatment of HER2 positive cancers 27 Apr, 2038
(13 years from now)
Active
US11504370 Treatment of brain cancer 25 Mar, 2033
(8 years from now)
Active
US9457093 Solid dispersions of a ERB2 (HER2) inhibitor 12 Oct, 2032
(7 years from now)
Active
US8648087 N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases 12 Apr, 2031
(6 years from now)
Active
US9693989 N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases 09 May, 2027
(2 years from now)
Active
US7452895 Quinazoline analogs as receptor tyrosine kinase inhibitors 16 Nov, 2024
(a month from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tukysa's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Seagen News

Approaches of Pfizer, Bristol Myers Squibb, and Johnson & Johnson in Tackling Patent Expirations

26 Jun, 2024

Pfizer targets development of 8 major cancer drugs by 2030, unveils focus areas - GVS HEALTH

14 Jun, 2024

Pfizer anticipates the development of 8 highly successful cancer drugs in various target areas.

13 Jun, 2024

Pfizer changes direction, shifting focus from COVID treatments to cancer drugs in an effort to regain market value

11 Mar, 2024

See More